TVTX Travere Therapeutics, Inc.
Healthcare$45.40+0.00%OpenMarket Cap: $4.22B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
41.34
P/S
7.71
EV/EBITDA
121.54
DCF Value
$-248.24
FCF Yield
0.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
-10.6%
Net Margin
-4.0%
ROE
-26.8%
ROA
-3.9%
ROIC
-13.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $127.2M | 79.0% | $-36.9M | $-37.1M | $— | — |
| Q4 null | $129.7M | 98.0% | $-32.4M | $2.7M | $— | — |
| FY null | $490.7M | 97.9% | $-62.8M | $-25.5M | $— | — |
| Q3 null | $164.9M | 99.0% | $24.9M | $25.7M | $— | — |
| Q2 null | $114.4M | 98.7% | $-12.7M | $-12.8M | $— | — |
| Q1 null | $81.7M | 94.3% | $-42.7M | $-41.2M | $— | — |
| Q4 null | $74.8M | 96.6% | $-60.7M | $-60.3M | $— | — |
| FY null | $233.2M | 96.7% | $-323.8M | $-321.5M | $— | — |
| Q3 null | $62.9M | 97.4% | $-56.1M | $-54.8M | $— | — |
| Q2 null | $54.1M | 77.1% | $-67.1M | $-70.4M | $— | — |
| Q1 null | $41.4M | 96.4% | $-139.2M | $-136.1M | $— | — |
| Q4 2023 | $45.1M | 63.6% | $-82.8M | $-90.2M | $-1.18 | — |